LON:COIL Roquefort Therapeutics (COIL) Share Price, News & Analysis GBX 11.78 +1.03 (+9.53%) As of 12:07 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Roquefort Therapeutics Stock (LON:COIL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Roquefort Therapeutics alerts:Sign Up Key Stats Today's Range 10▼ 1250-Day Range 7.10▼ 1152-Week Range 6.75▼ 12Volume1.25 million shsAverage Volume270,251 shsMarket Capitalization£50.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals. https://coiledplc.com/ Read More Receive COIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COIL Stock News HeadlinesCoiled Therapeutics PLCApril 1, 2026 | barrons.comRoquefort springs over to AIM from Main Market as Coiled TherapeuticsMarch 27, 2026 | lse.co.ukSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.May 22 at 1:00 AM | Behind the Markets (Ad)Coiled Therapeutics' Dr Sotirios Stergiopoulos on Roquefort RTO, AO-252 cancer trial updateMarch 9, 2026 | uk.finance.yahoo.comSmall cap idea: Why this £40m bet on an emerging cancer treatment may be perfectly timedMarch 9, 2026 | msn.comWhy this £40m bet on an emerging cancer treatment may be perfectly timedMarch 4, 2026 | uk.finance.yahoo.comRoquefort Therapeutics to acquire cancer drug licence in £32m RTO deal and raise £8.5mMarch 2, 2026 | uk.finance.yahoo.comTRADING UPDATES: Blencowe hits high grades; Roquefort advances trialDecember 12, 2025 | lse.co.ukSee More Headlines COIL Stock Analysis - Frequently Asked Questions How have COIL shares performed this year? Roquefort Therapeutics' stock was trading at GBX 12 on January 1st, 2026. Since then, COIL shares have decreased by 6.0% and is now trading at GBX 11.28. How were Roquefort Therapeutics' earnings last quarter? Roquefort Therapeutics plc (LON:COIL) announced its quarterly earnings data on Wednesday, May, 6th. The company reported ($2.19) earnings per share for the quarter. Roquefort Therapeutics had a negative trailing twelve-month return on equity of 18.30% and a negative net margin of 57,057.07%. When did Roquefort Therapeutics' stock split? Shares of Roquefort Therapeutics reverse split on Friday, March 27th 2026.The 1-10 reverse split was announced on Friday, March 27th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Roquefort Therapeutics? Shares of COIL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Roquefort Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Roquefort Therapeutics investors own include Vislink Technologies (XGTI), AutoZone (AZO), Intel (INTC), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), TJX Companies (TJX) and Abacus Health Products (ABAHF). Company Calendar Last Earnings5/06/2026Today5/22/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:COIL Previous SymbolLON:ROQ CIKN/A Webwww.roquefortinvest.com Phone44 20 3290 9339FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (6.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£1.52 million Net Margins-57,057.07% Pretax MarginN/A Return on Equity-18.30% Return on Assets-15.86% Debt Debt-to-Equity Ratio8.07 Current Ratio2.80 Quick Ratio3.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 7.88 per share Price / Cash Flow1.49 Book ValueGBX 3.82 per share Price / Book3.09Miscellaneous Outstanding Shares425,857,000Free FloatN/AMarket Cap£50.14 million OptionableNot Optionable Beta0.05 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:COIL) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredOne filing just changed the SpaceX IPO foreverSpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the larges...Behind the Markets | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
